Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Pharmena S.a. (PHR.WA)
PLN3.14
-0.01 (-0.32%)
PL WSE Healthcare Biotechnology
Address
Gdanska 47/49 90-729
Lódz, LDZ, PL
Lódz, LDZ, PL
CEO
Konrad Palka
Website
pharmena.eu
IPO
2010-02-22
ISIN PLPHRMN00011
Description
Pharmena S.A. engages in the sale of dietary supplements in Poland and internationally. It also develops 1-MNA (PHR-701 program), a medical device for use in difficult-to-heal wounds. In addition, the company is involved in research and development of therapeutic applications of 1 MNA as an anti-inflammatory and anti-fibrotic drug; and research and development at pulmonary fibrosis, respiratory tract infections, including viral infections, COVID-19, inflammatory diseases, metabolic diseases and other therapeutic applications. Pharmena S.A. was founded in 2002 and is based in Lódz, Poland. Pharmena S.A. operates as a subsidiary of Pelion S.A.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
PLN3.14
-0.01 (-0.32%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2.9K
Beta
0.56
Float Shares
1.99M
Free Float %
17.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +4.78% | -4.36% | -0.90% | +8.94% | +24.15% | -7.58% | -54.68% | -65.84% | -82.77% | -87.47% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
3.14
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
17.94
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+488.4% ★ Q1'26: +7.1% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-127.3% Q1'26: +8.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-219.5% Q1'26: -231.4% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-208.1% Q1'26: -114.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-34.0% Q1'26: -70.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.12× Q1'26: -0.19× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. |
Dec 2028 1 Rev. Ana. |
Dec 2029 1 Rev. Ana. |
Dec 2030 1 Rev. Ana. |
Dec 2031 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
17.47M
est: 16.50M (+5.9%)
|
15.91M
est: 11.14M (+42.9%)
|
12.51M
est: 18.42M (-32.1%)
|
13.04M
est: 16.16M (-19.3%)
|
11.10M
est: 13.20M (-15.9%)
|
9.93M
est: 21.84M (-54.5%)
|
15.21M
est: 29.91M (-49.1%)
|
299.0K
est: 41.30M (-99.3%)
|
18.42M
18.42M – 18.42M
-55.4% YoY
|
16.16M
16.16M – 16.16M
-12.3% YoY
|
13.20M
13.20M – 13.20M
-18.3% YoY
|
21.84M
21.84M – 21.84M
+65.5% YoY
|
29.91M
29.91M – 29.91M
+37.0% YoY
|
41.30M
41.30M – 41.30M
+38.1% YoY
|
| EBITDA |
-2.65M
est: -3.98M (+33.4%)
|
-819.0K
est: -2.69M (+69.5%)
|
-1.87M
est: -4.44M (+57.9%)
|
410.0K
est: -3.90M (+110.5%)
|
-9.65M
est: -3.18M (-203.0%)
|
-5.40M
est: -5.27M (-2.5%)
|
-3.52M
est: -7.22M (+51.3%)
|
-129.0K
est: -9.96M (+98.7%)
|
-6.12M
-6.12M – -6.12M
+38.5% YoY
|
-5.37M
-5.37M – -5.37M
+12.3% YoY
|
-4.39M
-4.39M – -4.39M
+18.3% YoY
|
-7.26M
-7.26M – -7.26M
-65.5% YoY
|
-9.95M
-9.95M – -9.95M
-37.0% YoY
|
-13.73M
-13.73M – -13.73M
-38.1% YoY
|
| EBIT |
-2.88M
est: -6.20M (+53.5%)
|
-1.09M
est: -4.19M (+73.9%)
|
-2.23M
est: -6.92M (+67.8%)
|
-9.0K
est: -6.07M (+99.9%)
|
-10.29M
est: -4.96M (-107.5%)
|
-6.03M
est: -8.21M (+26.6%)
|
-4.14M
est: -11.24M (+63.2%)
|
-4.06M
est: -15.52M (+73.8%)
|
-8.37M
-8.37M – -8.37M
+46.1% YoY
|
-7.34M
-7.34M – -7.34M
+12.3% YoY
|
-6.00M
-6.00M – -6.00M
+18.3% YoY
|
-9.92M
-9.92M – -9.92M
-65.5% YoY
|
-13.59M
-13.59M – -13.59M
-37.0% YoY
|
-18.77M
-18.77M – -18.77M
-38.1% YoY
|
| Net Income |
-3.62M
est: 93.61M (-103.9%)
|
-1.66M
est: 93.61M (-101.8%)
|
-2.39M
est: 93.61M (-102.6%)
|
-444.0K
|
-9.57M
|
-6.89M
|
-4.59M
|
-1.57M
|
93.61M
93.61M – 93.61M
|
—
— – —
-100.0% YoY
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| SGA |
15.38M
est: 95.35M (-83.9%)
|
12.54M
est: 64.38M (-80.5%)
|
10.85M
est: 106.45M (-89.8%)
|
8.64M
est: 93.39M (-90.7%)
|
17.54M
est: 76.28M (-77.0%)
|
11.15M
est: 126.22M (-91.2%)
|
12.02M
est: 172.85M (-93.0%)
|
3.84M
est: 238.68M (-98.4%)
|
112.76M
112.76M – 112.76M
-52.8% YoY
|
98.92M
98.92M – 98.92M
-12.3% YoY
|
80.80M
80.80M – 80.80M
-18.3% YoY
|
133.69M
133.69M – 133.69M
+65.5% YoY
|
183.09M
183.09M – 183.09M
+37.0% YoY
|
252.82M
252.82M – 252.82M
+38.1% YoY
|
| EPS |
-0.41
est: 8.40 (-104.9%)
|
-0.19
est: 8.40 (-102.3%)
|
-0.27
est: 8.40 (-103.2%)
|
-0.05
|
-0.95
|
-0.63
|
-0.41
|
-0.14
|
8.40
8.40 – 8.40
|
—
— – —
-100.0% YoY
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-09 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-06-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-06-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-06-03 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-06-02 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-06-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-3.44M
OE per share TTM
-0.31
Owner's Yield
-9.38%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
6.8%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-4.7K
Shares Outstanding
11.14M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Konrad Palka | President of Management Board, Chief Executive Officer & President | 300.0K | male |
| Marzena Wieczorkowska | Vice President of the Management Board and VP of Research & Development | 180.0K | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PHR.WA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
